Stem Cell Therapy Help Buddy the Beagle Buddy the beagle wasn't able to walk when he first arrived at the University of Minnesota Veterinary Medical Center. With the help of the Veterinary Medical ... By: UMN Health … Continue reading →

Plenary Session: Cell Therapy Product Development As more products head into later stage clinical development inevitably there will be successes and setbacks along the way. How do we educate key stakeholder ... By: Alliance for Regenerative Medicine … Continue reading →

CTVNews.ca Staff Published Saturday, October 25, 2014 10:30PM EDT Last Updated Saturday, October 25, 2014 11:46PM EDT An estimated 16,000 Canadians live with scleroderma, an incurable autoimmune disorder which causes the body to produce too much collagen, resulting in a hardening of the skin and tissue. There is no cure for the scleroderma, but some patients in Canada are now seeking a costly and experimental stem cell therapy in the U.S. A little over a year ago, Mike Berry of Kingston, Ont., started having trouble breathing. It was the first sign of scleroderma. Berry, 42, suffers from the systemic version of scleroderma, which attacks his internal organs. His lungs have been scarred by the disorder, with his lung capacity dropping to 41 per cent in just nine months. His disease may ultimately be fatal. He described to CTV News how scleroderma has impacted his day-to-day life. "I'm unable to work any longer; it affects me and everything now," he said. "It's hard to walk fast; I can't walk and talk." Drugs to treat his scleroderma haven't worked, so now Berry is trying to fundraise more than $150,000 for an experimental U.S. stem cell treatment called Autologous Hematopoietic Stem Cell Transplantation … Continue reading →

Living Cell Technologies collaborates to develop novel neurological treatments Living Cell Technologies Limited has formed a collaboration with the Centre for Brain Research (CBR). The research collaboration will identify additional neurodegenerative disease targets for clinical studies of LCTs lead product NTCELL. Directed by Professor Richard Faull, ONZM MBChB PhD DSc FRSNZ, University of Auckland Distinguished Professor, the CBR has a specialised interest in neurodegenerative diseases such as Parkinsons, Huntingtons, motor neurone and Alzheimers diseases. LCT has the expertise to identify and commercialise treatments and products from CBR research. Its therapeutic treatment NTCELL is currently in a Phase I/IIa clinical study targeting Parkinsons patients who have failed current symptomatic therapy. Professor Richard Faull said, The results of LCTs research studies are impressive and provide strong evidence that NTCELL has the potential to provide significant improvement in patients with Parkinsons disease. We believe this collaboration can help realise the potential of cell therapy for neurodegenerative diseases. Dr Ken Taylor, LCT chief executive said, The collaboration is in line with our focus to develop and market NTCELL therapy for Parkinsons patients failing current therapy while also investigating the potential of our patented cell therapy for other neurodegenerative disorders. Ends For further information: http://www.lctglobal.com … Continue reading →